Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCM
MCID: MNT001
MIFTS: 66

Mantle Cell Lymphoma (LCM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mantle Cell Lymphoma

About this section

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 12 74 52 58 36 29 6 15 37 17 32
Lcm 58 3
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 71
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 71
Lymphoma, Mantle Cell 52
Lymphoma, Mantle-Cell 43
Mantle Zone Lymphoma 58
Lymphoma Mantle-Cell 54
Mcl 58

Characteristics:

Orphanet epidemiological data:

58
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050746
KEGG 36 H01464
MeSH 43 D020522
ICD10 32 C83.1
MESH via Orphanet 44 D020522
ICD10 via Orphanet 33 C83.1
UMLS via Orphanet 72 C0555202
Orphanet 58 ORPHA52416
UMLS 71 C0334634 C0555202
Sources

Summaries for Mantle Cell Lymphoma

About this section
CDC : 3 Lymphocytic choriomeningitis, or LCM, is a rodent-borne viral infectious disease caused by lymphocytic choriomeningitis virus (LCMV), a member of the family Arenaviridae, that was initially isolated in 1933. The primary host of LCMV is the common house mouse, Mus musculus. Infection in house mouse populations may vary by geographic location, though it is estimated that 5% of house mice throughout the United States carry LCMV and are able to transmit virus for the duration of their lives without showing any sign of illness. Other types of rodents, such as hamsters, are not the natural reservoirs but can become infected with LCMV from wild mice at the breeder, in the pet store, or home environment. Humans are more likely to contract LCMV from house mice, but infections from pet rodents have also been reported.

MalaCards based summary : Mantle Cell Lymphoma, also known as lcm, is related to follicular lymphoma and hairy cell leukemia. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Measles and Chks in Checkpoint Regulation. The drugs Orange and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are lymphadenopathy and b-cell lymphoma

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

NIH Rare Diseases : 52 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system ). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s.

KEGG : 36 Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) and it accounts for about 6% of all NHL cases. Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. The molecular hallmark and putative initiating oncogenic event in MCL is the t(11;14)(q13;q32) translocation resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course.

Wikipedia : 74 Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases.... more...

Sources

Related Diseases for Mantle Cell Lymphoma

About this section

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 33.7 MIR17 MIR155 IGH EZH2 CD5 CCND1
2 hairy cell leukemia 33.5 TP53 CD5 CCND1
3 lymphoma 32.7 TP53 MDM2 GAS5 EZH2 CD5 CCND1
4 lymphocytic leukemia 32.5 TP53 MIR155 CD5 CCND1 BTK BCL2
5 lymphoma, non-hodgkin, familial 32.4 TP53 MIR17 MIR155 MDM2 IGH EZH2
6 marginal zone b-cell lymphoma 32.4 CD5 CCND1 BCL6 BCL2
7 leukemia, chronic lymphocytic 32.2 TP53 MIR17 MIR16-1 MIR155 MDM2 IGH
8 diffuse large b-cell lymphoma 32.1 TP53 MIR17 MIR155 MDM2 EZH2 CD5
9 cll/sll 32.0 TP53 EZH2 CD5 CCND1 BTK BCL6
10 lymphoma, mucosa-associated lymphoid type 31.9 TP53 IGH CD5 CCND1 BCL6 BCL2
11 burkitt lymphoma 31.9 TP53 SOX11 MIR155 CCND1 BMI1 BCL6
12 prolymphocytic leukemia 31.8 TP53 CD5 CCND1 ATM
13 splenic marginal zone lymphoma 31.8 CD5 BTK BCL6
14 autoimmune lymphoproliferative syndrome, type v 31.7 IGH CD5 BCL6
15 adenocarcinoma 31.7 TP53 MDM2 MALAT1 CCND1 BCL2
16 b-cell lymphoma 31.7 TP53 MIR17 MIR155 MDM2 MALAT1 IGH
17 nodal marginal zone lymphoma 31.7 IGH CD5 BCL6
18 richter's syndrome 31.6 TP53 CD5 ATM
19 lymphoplasmacytic lymphoma 31.6 MIR155 IGH CD5 CCND1 BTK
20 lymphosarcoma 31.6 IGH BCL6 BCL2
21 gastrointestinal lymphoma 31.6 CD5 CCND1 BCL6
22 prostate lymphoma 31.6 CD5 BCL6
23 myelodysplastic syndrome 31.5 TP53 MDM2 EZH2 BTK BMI1 BCL2
24 mature b-cell neoplasm 31.5 TP53 MIR17 MIR155 CD5 CCND1 BCL6
25 retinoblastoma 31.5 TP53 MDM2 MALAT1 CCNG1 CCND1
26 leukemia, chronic lymphocytic 2 31.5 CD5 BCL2 ATM
27 peripheral t-cell lymphoma 31.4 TP53 CD5 CCND1 BCL6 ATM
28 suppression of tumorigenicity 12 31.4 TP53 MDM2 EZH2 CCND1 ATM
29 lymphoblastic lymphoma 31.4 TP53 CD5 BCL6
30 b cell prolymphocytic leukemia 31.4 TP53 CD5
31 plasma cell neoplasm 31.3 TP53 CD5 CCND1 BCL6
32 nodal marginal zone b-cell lymphoma 31.3 BCL6 BCL2
33 leukemia, acute myeloid 31.2 TP53 MIR17 MIR155 MDM2 MALAT1 EZH2
34 leukemia, chronic myeloid 31.2 TP53 MIR17 MIR155 CCND1 BMI1 BCL2
35 plasmacytoma 31.2 IGH CD5 CCND1
36 colon lymphoma 31.2 CD5 BCL6
37 myeloma, multiple 31.0 TP53 MIR17 MIR155 MDM2 MALAT1 GAS5
38 reticulosarcoma 31.0 IGH BCL6 BCL2
39 acute t cell leukemia 31.0 TP53 MIR17 EZH2 CD5
40 leukemia, acute lymphoblastic 31.0 MIR17 MIR155 MDM2 IGH CD5 BTK
41 acute promyelocytic leukemia 31.0 MIR16-1 EZH2 CCND1 BCL6 BCL2
42 bone lymphoma 31.0 CD5 BCL6
43 basal cell carcinoma 31.0 TP53 MDM2 CCND1 BMI1 BCL2
44 hematologic cancer 31.0 TP53 MIR17 MIR16-1 MIR155 CD5 CCND1
45 pancreatic adenocarcinoma 30.9 TP53 MIR155 MDM2 CCND1 BMI1 BCL2
46 lung lymphoma 30.9 CD5 BCL6
47 primary mediastinal b-cell lymphoma 30.9 MIR155 BCL6 BCL2
48 lung cancer susceptibility 3 30.8 TP53 MIR17 MDM2 MALAT1 GAS5 EZH2
49 breast lymphoma 30.8 CD5 BCL6
50 clear cell renal cell carcinoma 30.8 TP53 MIR155 MDM2 MALAT1 EZH2 CCND1

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma
Sources

Symptoms & Phenotypes for Mantle Cell Lymphoma

About this section

Human phenotypes related to Mantle Cell Lymphoma:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
2 b-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012191
3 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
6 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 abnormality of bone marrow cell morphology 58 31 frequent (33%) Frequent (79-30%) HP:0005561
9 abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0011024

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.65 ATM BCL2 BCL6 BTK CCND1 CD5
2 neoplasm MP:0002006 9.23 ATM BCL2 BTK CCND1 CCNG1 EZH2
Sources

Drugs & Therapeutics for Mantle Cell Lymphoma

About this section

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Idarubicin Approved Phase 3 58957-92-9 42890
4
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Ribavirin Approved Phase 3 36791-04-5 37542
9
Chlorambucil Approved Phase 3 305-03-3 2708
10
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
11
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
12
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
15
Dalteparin Approved Phase 3 9005-49-6
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
20
Piperacillin Approved Phase 3 66258-76-2 43672
21
Tazobactam Approved Phase 3 89786-04-9 123630
22
Vancomycin Approved Phase 3 1404-90-6 441141 14969
23
Acyclovir Approved Phase 3 59277-89-3 2022
24
Palivizumab Approved, Investigational Phase 3 188039-54-5
25
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
26
Captopril Approved Phase 3 62571-86-2 44093
27
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
28
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
29
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
30
tannic acid Approved Phase 3 1401-55-4
31
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
32
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
33
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
34
Polyestradiol phosphate Approved Phase 3 28014-46-2
35
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
36
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
37
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
38
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
39 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
40 Interferon alpha-2 Phase 3
41 Interferon-alpha Phase 3
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
43 Amoxicillin-Potassium Clavulanate Combination Phase 3
44 Anesthetics, Dissociative Phase 3
45 Pharmaceutical Solutions Phase 3
46 Neurotransmitter Agents Phase 3
47 Cytochrome P-450 CYP3A Inhibitors Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 3
49 Steroid Synthesis Inhibitors Phase 3
50 Cytochrome P-450 CYP2C9 Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 1050)
# Name Status NCT ID Phase Drugs
1 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
5 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
6 Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Unknown status NCT01449344 Phase 3 Rituximab;High dose Ara-C;Dexamethasone;Bortezomib
7 Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation Unknown status NCT00209209 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Fludarabine;Interferon-alpha;pegylated formula Interferon-alpha 2b
8 Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9 Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
10 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
11 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
12 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
13 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
14 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
15 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
17 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
19 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
20 Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL Completed NCT00921414 Phase 3 Rituximab
21 An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22 A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4 Completed NCT00003280 Phase 3
23 Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma Completed NCT00641095 Phase 2, Phase 3 Cyclophosphamide;Fludarabine
24 A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
25 An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
26 A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
27 A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
28 Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
29 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
30 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
31 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
32 A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
33 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
34 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
35 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
36 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
37 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
39 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
40 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
42 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
43 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
44 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
45 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
46 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
47 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
48 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
49 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
50 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ibrutinib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Peripheral blood stem cells for treatment of hematologic malignancies
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: lymphoma, mantle-cell

Sources

Genetic Tests for Mantle Cell Lymphoma

About this section

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29
Sources

Anatomical Context for Mantle Cell Lymphoma

About this section

MalaCards organs/tissues related to Mantle Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Breast
Sources

Publications for Mantle Cell Lymphoma

About this section

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 4547)
# Title Authors PMID Year
1
Mantle cell lymphoma is characterized by inactivation of the ATM gene. 61 6
10706620 2000
2
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. 61 46
18483394 2008
3
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 54 61
20062012 2010
4
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. 54 61
18606985 2008
5
Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. 54 61
17488676 2007
6
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. 54 61
17145584 2006
7
Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. 54 61
16956411 2006
8
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. 54 61
16448697 2006
9
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. 54 61
11389032 2001
10
Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. 54 61
9846986 1998
11
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. 54 61
9209645 1997
12
Chronic lymphoproliferative disorders. 54 61
9090492 1997
13
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. 54 61
8695815 1996
14
Mantle-cell lymphoma: classification and therapeutic implications. 54 61
9010577 1996
15
Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. 54 61
7772515 1995
16
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. 54 61
8204893 1994
17
PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. 54 61
7918073 1994
18
Identification of genetic lesions associated with diffuse large-cell lymphoma. 54 61
8172819 1994
19
Gastrointestinal Mantle Cell Lymphoma with Varied Findings. 61
31309435 2020
20
[Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review]. 61
32027299 2020
21
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. 61
31846632 2020
22
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. 61
32029507 2020
23
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. 61
32033280 2020
24
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. 61
31610237 2020
25
Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study. 61
31688139 2020
26
Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma. 61
31408711 2020
27
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. 61
32011729 2020
28
Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. 61
32034308 2020
29
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. 61
31853704 2020
30
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib. 61
31893998 2020
31
Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma. 61
31685258 2020
32
Orbital soft tissue composite lymphoma presenting as recurrence of a nodal lymphoma with mantle and follicular cell components: A case report, literature review and guideline for the treatment of patients. 61
31932010 2020
33
Zanubrutinib: First Approval. 61
31933167 2020
34
Protean Manifestations and Diagnostic Challenges Including Discordance Between Electrodiagnostic-Radiologic Studies in Neurolymphomatosis. 61
31876651 2020
35
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. 61
31971032 2020
36
A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline. 61
31629393 2020
37
The double dealing of cyclin D1. 61
31885322 2020
38
Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases 61
32003552 2020
39
LncRNA ROR1‑AS1 high expression and its prognostic significance in liver cancer. 61
31746401 2020
40
Mechanisms of resistance to mTOR inhibitors. 61
32014673 2020
41
Alleviating effect of paeoniflorin-6'-O-benzene sulfonate in antigen-induced experimental Sjögren's syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway. 61
31955068 2020
42
Correction: Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. 61
31471573 2020
43
Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45+CD19- cells but in the ALDHhigh Cells. 61
31892981 2020
44
Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. 61
32019190 2020
45
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. 61
31822509 2020
46
Acute cutaneous botryomycosis of the hands. 61
32025493 2020
47
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report. 61
32021859 2020
48
Mantle cell lymphoma mimicking adult T-cell leukemia. 61
32019688 2020
49
Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience. 61
30924740 2020
50
25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma. 61
31915915 2020
Sources

Variations for Mantle Cell Lymphoma

About this section

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.7268A>G (p.Glu2423Gly)SNV Pathogenic 3039 rs121434221 11:108199926-108199926 11:108329199-108329199
2 ATM NM_000051.3(ATM):c.7251_7253dup (p.Lys2418dup)duplication Pathogenic 3040 rs796051857 11:108199908-108199909 11:108329181-108329182
3 ATM NM_000051.3(ATM):c.4081C>T (p.Gln1361Ter)SNV Pathogenic 3041 rs121434222 11:108158414-108158414 11:108287687-108287687

Cosmic variations for Mantle Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87898723 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.817C>T p.R273C 17:7673803-7673803 0

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma
Sources

Expression for Mantle Cell Lymphoma

About this section
Search GEO for disease gene expression data for Mantle Cell Lymphoma.
Sources

Pathways for Mantle Cell Lymphoma

About this section

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Measles 36
Show member pathways
 12.75 TP53 MDM2 CCND1 BTK BCL2
2
Chks in Checkpoint Regulation 63
Show member pathways
 12.62 TP53 MDM2 CCND1 BCL2 ATM
3
Glioma 36
Show member pathways
 12.6 TP53 MDM2 CCND1 BCL2 ATM
4
Apoptosis Pathway 70
Show member pathways
 12.38 TP53 MDM2 BCL2 ATM
5
Development IGF-1 receptor signaling 22
Show member pathways
 12.32 TP53 MDM2 IGH CCND1
6
Shigellosis 36
12.31 TP53 MDM2 BCL2 ATM
7
Cell cycle 1 36
12.29 TP53 MDM2 CCND1 ATM
8
p53 Signaling 63
Show member pathways
 12.2 TP53 MDM2 CCND1 BCL2 ATM
9
Transcriptional misregulation in cancer 36
12.18 TP53 MDM2 BMI1 BCL6 ATM
10
Cellular senescence (KEGG) 36
12.09 TP53 MDM2 CCND1 ATM
11
Integrated Breast Cancer Pathway 1
12.06 TP53 MDM2 CCND1 BCL2 ATM
12
FoxO signaling pathway 36
Show member pathways
 12.01 MDM2 CCND1 BCL6 ATM
13
Direct p53 effectors 1
11.95 TP53 MDM2 CCNG1 BCL6 BCL2
14
Interleukin-4 and 13 signaling 65
11.93 TP53 CCND1 BCL6 BCL2
15
DNA Damage Response 1
Show member pathways
 11.93 TP53 MIR17 MIR16-1 MDM2 CCNG1 CCND1
16
MicroRNAs in cancer 36
11.89 TP53 MIR26A1 MIR17 MIR16-1 MIR155 MDM2
17
Senescence and Autophagy in Cancer 1
11.88 TP53 MDM2 BMI1 BCL2
18
Small cell lung cancer 36
11.8 TP53 CCND1 BCL2
19
Retinoblastoma (RB) in Cancer 1
11.77 TP53 MDM2 CCND1
20
ATM Pathway 63
Show member pathways
 11.76 TP53 MDM2 ATM
21
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.71 TP53 MDM2 CCNG1 ATM
22
Platinum drug resistance 36
11.7 TP53 MDM2 BCL2 ATM
23
DNA Damage Response (only ATM dependent) 1
11.69 TP53 MDM2 CCND1 BCL6 BCL2 ATM
24
Bladder cancer 36 1
11.66 TP53 MDM2 CCND1
25
Transcription_P53 signaling pathway 22
11.63 TP53 MDM2 BCL2 ATM
26
p53 pathway 1
11.57 TP53 MDM2 CCNG1 ATM
27
Copper homeostasis 1
11.51 TP53 MDM2 CCND1
28
Photodynamic therapy-induced AP-1 survival signaling. 1
11.48 TP53 CCND1 BCL2
29
miRNAs involved in DNA damage response 1
11.46 TP53 MIR16-1 CCND1 ATM
30
Integrated Cancer Pathway 1
11.37 TP53 MDM2 BCL2 ATM
31
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.31 TP53 MDM2 CCND1 ATM
32
GADD45 Pathway 63
11.13 TP53 CCNG1 CCND1 ATM
33
TP53 Network 1
Show member pathways
 10.9 TP53 MDM2 BCL2 ATM
Sources

GO Terms for Mantle Cell Lymphoma

About this section

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.08 SOX11 MDM2 EZH2 CCND1 BCL2
2 cellular response to DNA damage stimulus GO:0006974 10.05 TP53 CCND1 BCL6 BCL2 ATM
3 positive regulation of gene expression GO:0010628 10.03 TP53 SOX11 MIR155 MDM2 ATM
4 negative regulation of cell proliferation GO:0008285 10.03 TP53 MIR26A1 MIR16-1 BCL6 BCL2
5 negative regulation of transcription by RNA polymerase II GO:0000122 10.02 TP53 SOX11 MDM2 EZH2 CCND1 BMI1
6 gene silencing by miRNA GO:0035195 9.98 MIR26A1 MIR17 MIR16-1 MIR155
7 regulation of gene expression GO:0010468 9.96 MDM2 EZH2 BMI1 BCL2
8 cell proliferation GO:0008283 9.94 TP53 SOX11 CD5 BCL2
9 regulation of cell proliferation GO:0042127 9.92 TP53 MIR155 EZH2 BCL6
10 regulation of apoptotic process GO:0042981 9.85 TP53 MIR155 BCL6 BCL2 ATM
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.78 TP53 MDM2 ATM
12 positive regulation of fibroblast proliferation GO:0048146 9.77 MIR17 MIR155 BMI1
13 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR26A1 MIR17 MDM2
14 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.74 MIR26A1 MIR16-1 MIR155
15 neuron apoptotic process GO:0051402 9.73 TP53 BCL2 ATM
16 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.72 TP53 MIR16-1 BCL2
17 negative regulation of mitotic cell cycle GO:0045930 9.71 TP53 MIR16-1 BCL2
18 cellular response to organic substance GO:0071310 9.7 MDM2 CCND1 BCL2
19 positive regulation of connective tissue replacement GO:1905205 9.68 MIR16-1 MIR155
20 cardiac septum morphogenesis GO:0060411 9.68 TP53 MDM2
21 replicative senescence GO:0090399 9.67 TP53 ATM
22 oocyte development GO:0048599 9.67 BCL2 ATM
23 response to magnesium ion GO:0032026 9.67 MDM2 CCND1
24 response to steroid hormone GO:0048545 9.67 MDM2 CCND1 BCL2
25 positive regulation of histone deacetylation GO:0031065 9.66 TP53 BCL6
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.65 MIR17 MIR155
27 regulation of mitochondrial membrane permeability GO:0046902 9.65 TP53 BCL2
28 response to UV-B GO:0010224 9.64 TP53 BCL2
29 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
30 cellular response to UV-C GO:0071494 9.61 TP53 MDM2
31 cellular response to gamma radiation GO:0071480 9.61 TP53 MDM2 ATM
32 T cell lineage commitment GO:0002360 9.6 TP53 BCL2
33 B cell lineage commitment GO:0002326 9.58 TP53 BCL2
34 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.58 MIR26A1 MIR16-1 MIR155
35 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.56 MIR26A1 MIR16-1 EZH2 BCL2
36 regulation of cell cycle GO:0051726 9.55 TP53 CCNG1 CCND1 BCL2 ATM
37 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.54 TP53 MIR17 MIR16-1
38 cellular response to actinomycin D GO:0072717 9.51 TP53 MDM2
39 response to iron ion GO:0010039 9.5 MDM2 CCND1 BCL2
40 negative regulation of gene expression GO:0010629 9.43 TP53 SOX11 MIR17 MIR155 MDM2 EZH2
41 cellular response to hypoxia GO:0071456 9.1 TP53 MIR17 MIR155 MDM2 MALAT1 BCL2

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR26A1 MIR17 MIR16-1 MIR155
2 promoter-specific chromatin binding GO:1990841 8.8 TP53 EZH2 BMI1
Sources

Sources for Mantle Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....